- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2018–2023 · research · R01
Integrative Somatic and Germline Computational Biology to Redefine Clinical Actionability in Solid Tumors
Eliezer M Van Allen · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2024 · cooperative agreement · U24
Human Tumor Atlas Network: Data Coordinating Center
Ethan Cerami · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R37
Targeting blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Andrew A Lane · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · cooperative agreement · U01
End-of-Life Care for Adolescents and Young Adults with Cancer: An Evaluation of Care and Development of Patient-Centered Quality Measures
Jennifer W Mack · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2025 · cooperative agreement · UH3
Improving Advance Care Planning in Oncology: A Pragmatic, Cluster-Randomized Trial Integrating Patient Videos and Clinician Communication Training
James A. Tulsky · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2019 · career development · K99
The role of Fusobacterium in colorectal cancer treatment, tumor ecology and chemotherapeutic efficacy
Susan Bullman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2022 · career development · K00
The Role of E2F2 in HER2 Positive Breast Cancer
Jonathan Rennhack · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · cooperative agreement · U01
Molecular and immune drivers of immunotherapy responsiveness in prostate cancer
Lawrence Fong · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2024 · cooperative agreement · U2C
The Cellular Geography of Therapeutic Resistance in Cancer
Eliezer M Van Allen · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R01
Hematopoietic stem cell gene therapy for infantile neuronal ceroid lipofuscinosis
Christian Brendel · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2019 · fellowship · F32
Signaling dynamics and cellular context as drivers of the heterogeneity of macrophage infection by M. tuberculosis
Amy Thurber Moody · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · cooperative agreement · UH3
Improving Advance Care Planning in Oncology: A Pragmatic, Cluster-Randomized Trial Integrating Patient Videos and Clinician Communication Training
James A. Tulsky · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2024 · research · R01
Dissecting neoepitope-specific clonal T cell populations in advanced melanoma patients vaccinated with personal neoantigen peptides partnered with local and systemic immune checkpoint Inhibition
Patrick Alexander Ott · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2021 · research · R00
Characterizing the resistance mechanisms to BET-bromodomain inhibition in MYC-amplified medulloblastoma
Pratiti Bandopadhayay · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R01
EZH2 in cancer biology and novel inhibitors
Jun Qi · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · career development · K07
Obesity and Pancreatic Cancer Progression and Survival
Ana Babic · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · cooperative agreement · U01
Rewiring of regulatory networks in breast cancer by transcription factor isoforms
Martha L Bulyk · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2022 · career development · K00
Metabolically active macrophages: a novel link between obesity and triple negative breast cancer
Payal Tiwari · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2020 · grant · LCRP
Ultrasensitive Detection of Subclinical Lung Cancer by Statistical Analysis of Plasma cfDNA-Derived Whole-Genome Sequencing Data
Scott Carter · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2018–2025 · research · R35
Development of Combination Therapies to Delay/Prevent Acquired Drug Resistance
Pasi A Janne · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R01
Novel therapeutic approaches with CDK4/6 inhibitors for melanoma treatment
Peter Sicinski · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2022 · cooperative agreement · U01
Bioinformatics Technology to Characterize Tumor Infiltrating Immune Repertoires
Heng Li · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R37
Molecular origins and evolution to chemoresistance in germ cell tumors
Eliezer M Van Allen · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · career development · K08
Dissecting Therapeutic Resistance and Progression in Metastatic Melanoma Through Clinical Computational Oncology
David Liu · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R01
KDM5 histone lysine demethylases as potential novel myeloid tumor suppressors
Julie-Aurore Losman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2024 · research · R01
Novel therapeutic approaches with CDK4/6 inhibitors for melanoma treatment
Peter Sicinski · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2026 · research · R01
Comprehensive minimal residual disease tracking in cancer
Viktor Adalsteinsson · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · cooperative agreement · U01
Rewiring of regulatory networks in breast cancer by transcription factor isoforms
Martha L Bulyk · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · cooperative agreement · U01
Rewiring of regulatory networks in breast cancer by transcription factor isoforms
Martha L Bulyk · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · career development · K08
Targeting casein kinase 1-alpha for cancer therapy
Steven Muntean Corsello · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R01
KDM5 histone lysine demethylases as potential novel myeloid tumor suppressors
Julie-Aurore Losman · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R01
Immunotherapeutic responses to neoantigens in head and neck cancer
Ravindra Uppaluri · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · career development · K07
Obesity and Pancreatic Cancer Progression and Survival
Ana Babic · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2024 · career development · K00
Investigating molecular mechanism of immune response during cancer progression
Zeyu Chen · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R01
Degrading therapeutically important kinases using small molecules
Eric Sebastian Fischer · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R01
Effects of marijuana use on inflammation and vascular injury in adults with HIV infection
Dana H. Gabuzda · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2027 · research · R01
Advanced computational methods in analyzing high-throughput sequencing data
Heng Li · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2027 · research · R01
Advanced computational methods in analyzing high-throughput sequencing data
Heng Li · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2021 · fellowship · F32
The molecular basis of substrate specificity for a small molecule ubiquitin ligase complex
Tyler B Faust · Dana-Farber Cancer Institute · funded by National Institutes of Health
2018–2023 · research · R01
Integrative Somatic and Germline Computational Biology to Redefine Clinical Actionability in Solid Tumors
Eliezer M Van Allen · Dana-Farber Cancer Institute · funded by National Institutes of Health
